Live Chat

Giao dịch Vir Biotechnology VIR

VirBiotechnology biểu đồ trực tiếp

Kiến thức cơ bản về công cụ

Weekly Search
Weekly
Daily
Ngày Đóng Thay đổi % Thay đổi Mở Cao Thấp

Tin tức mới nhất

Frances Wang 2025 Mar 09, 16:00

Stock market today: data on Nasdaq, S&P 500, Dow, and Russell 2000

Stocks
Tommy Yap 2025 Mar 09, 16:00

Morning Note: Carney Becomes Canada’s PM, China CPI Drops, and Oracle Earnings Loom

Morning Note CAD China CPI
Frances Wang 2025 Mar 06, 16:00

Investing news: Asian Stocks and Bitcoin Decline Amid Souring Sentiment

Stocks
Tommy Yap 2025 Mar 06, 16:00

Morning Note: U.S. Jobs Data, Trump’s Bitcoin Reserve, and Canada’s Unemployment Rate

Morning Note USD CAD Cryptocurrencies
Frances Wang 2025 Mar 05, 16:00

Forex market today: AUD/JPY Price Forecast

Forex
Frances Wang 2025 Mar 05, 16:00

Baron Oil news today: What is happening with BOIL stock?

Oil
Frances Wang 2025 Mar 05, 16:00

Stock market today: Dow and S&P 500 remain steady on Trump’s tariff pause

Stocks Shares
Tommy Yap 2025 Mar 05, 16:00

Morning Note: Broadcom’s AI-Driven Earnings, ECB Rate Cut, and US Jobless Claims

Morning Note USD

Thông tin

Chênh lệch

0.05

Tỷ lệ Spread (%)

0.6803 %

Đòn bẩy

1:5

Lãi suất Qua đêm Mua

-0.0597 %

Lãi suất Qua đêm Bán

-0.0292 %

Forex

USD

Giờ giao dịch

Thị trường đã đóng cửa.

Thứ ba

13:31 - 19:59

Thứ hai

13:31-19:59

Thứ tư

13:31-19:59

Thứ năm

13:31-19:59

Thứ sáu

13:31-19:59

Phân tích và thống kê

Mở

---

Đóng trước đó

---

52 Tuần Cao/Thấp

--- – ---

Giá trị vốn hóa thị trường

1091658368

Cổ phiếu nổi bật

137143008

Ngày báo cáo thu nhập (tiếp theo)

0000-00-00

Tỷ suất cổ tức

Ngày giao dịch không hưởng quyền

Tỷ lệ cổ tức thường niên kỳ hạn

0

Tỷ suất cổ tức thường niên kỳ hạn

0

EPS

-3.83

Tìm hiểu thêm về công cụ này

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Các công cụ liên quan

Các công cụ liên quan
Trustpilot
Live Chat